This record was last updated August 6, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-02-08; most recent amendment 2024-08-04.